Molecular tumour board in gastrointestinal cancers.

ABSTRACT:

Background

Comprehensive genomic profiling (CGP) is being increasingly adopted in clinical practice to guide the use of molecularly guided treatment options (MGTOs). To optimize the integration of MGTOs in routine cancer care, molecular tumour boards (MTBs) have been established. Limited data are available to address the clinical value of implementing MTBs to inform treatment decision making in patients with gastrointestinal (GI) cancers.

Materials and methods

We retrospectively retrieved medical records from patients with advanced GI cancers discussed at the European Institute of Oncology's MTB between August 2019 and December 2024. We evaluated clinical outcomes resulting from applying MGTOs in cancer care according to MTB recommendations, describing real-world progression

SUBMITTER: Boscolo Bielo L 

PROVIDER: S-EPMC11979463 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature